Comparative Performance of Four AI Systems for Detecting Referable Diabetic Retinopathy in Tanzania: A Real-World Evaluation

Highlight

This head-to-head comparative study evaluated four commercial artificial intelligence (AI) systems—Medios AI/Remidio, MONA, Ophtai, and SELENA+—for diabetic retinopathy (DR) detection in a Tanzanian population, revealing sensitivities of 83.9% to 93.7% for referable DR and over 98% for proliferative DR. All systems had regulatory approval, with one capable of offline use. These findings support AI’s role in expanding DR screening access in low-resource settings.

Study Background